Finn from Germany

Registered at the short selling broker Skilling, 3 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Novartis AG (NVS) shares information

Novartis AG


24h Change

0.60 %

NVS

Live rate: Market closed

Stock data per Tuesday 4 Aug, 2020

NVS
New York Stock Exchange
83.65
83.65
84.15
0.5 (+ 0.60%)
US Market is closed

Live Stock price in graph for Novartis AG (NVS)

  • Latest Volume

    2,115,513 (-12.19 %)

  • Volume prev. day

    2,409,103

  • Avg. daily volume

    1,567,921

  • Market cap

    190,600,058,662

  • P/E ratio

    26.54

  • Today high

    84.42

  • Today low

    83.36

  • 52 week high

    99.84

  • 52 week low

    69.18

  • YTD Change

    n/a

Quick links

Broker recommendations for Novartis AG

The Novartis AG stock is rated at 1.522727 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 9 July, 2020 by a total of 22 brokers. This means that the consensus of the 22 different brokers is leaning toward to overweight (moderate buy).

Sell
2 (9.09%)
Underweight
0 (0%)
Hold
6 (27.27%)
Overweight
3 (13.64%)
Buy
11 (50%)

Price target by analysts

The 18 latest analyst estimates, per Saturday 1 August, 2020, show the following high, low and average price targets.
Target Average: 102.64 USD
Target High: 115.8 USD
Target Low: 82.44 USD

 

Latest news about Novartis AG

Below you can find the most recent news posts about Novartis AG, primarily from US and UK based news sources.

Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma

Tuesday, 4 August 2020, 07:15:08
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory follicular lymphoma as measured by complete response rate Kymriah previously…
— MarketScreener


SEC’s Pathetic Agreement With Bausch Health Companies

Monday, 3 August 2020, 23:10:23
Whitney Tilson’s email to investors discussing SEC’s pathetic agreement with Bausch Health Companies Inc (NYSE:BHC) (formerly Valeant); Insys documentary; Opioids, Bribery, and Wall Street; Novartis bribery settlement; Kodak. Q2 2020 hedge fund letters, conferences and more SEC’s Pathetic Agreement With Bausch Health Companies 1) On Friday, the U.S. Securities and Exchange Commission (“SEC”) announced a […] The post SEC’s Pathetic Agreement With Bausch Health Companies appeared first on ValueWalk .
— ValueWalk


Collaborating to explore new gene regulation therapies | Novartis

Thursday, 30 July 2020, 15:34:00
Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.
— Novartis


COVID-19 Impacts: Allergy Rhinitis Drugs Market will Accelerate at a CAGR of almost 4% through 2020-2024 | Increasing Prevalence Of Allergic Rhinitis to Boost Growth | Technavio

Thursday, 30 July 2020, 04:00:00
Technavio has been monitoring the allergy rhinitis drugs market and it is poised to grow by USD 2.4 bn during 2020-2024, progressing at a CAGR of almost 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005699/en/ Technavio has announced its latest market research report titled Global Allergy Rhinitis Drugs Market 2020-2024 (Graphic: Business Wire). Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Alcon Inc., ALK-Abello AS, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and Stallergenes Greer Ltd. are some of the major market participants.
— Benzinga


The Big Interview: Novartis CTO Elizabeth Theophille

Wednesday, 29 July 2020, 15:10:18
“One of our big focuses for the next four-six years will be to refresh our SAP landscape which will require a complete overhaul…” The post The Big Interview: Novartis CTO Elizabeth Theophille appeared first on Computer Business Review .
— Computer Business Review Online